Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether there is an increased risk of cardiovascular events in people who exhibit iatrogenic Cushing's syndrome during treatment with glucocorticoids. DESIGN: Cohort study. SETTING: 424 UK general practices contributing to The Health Improvement Network database. PARTICIPANTS: People prescribed systemic glucocorticoids and with a diagnosis of iatrogenic Cushing's syndrome (n = 547) and two comparison groups: those prescribed glucocorticoids and with no diagnosis of iatrogenic Cushing's syndrome (n = 3231) and those not prescribed systemic glucocorticoids (n = 3282). MAIN OUTCOME MEASURES: Incidence of cardiovascular events within a year after diagnosis of iatrogenic Cushing's syndrome or after a randomly selected date, and association between iatrogenic Cushing's syndrome and risk of cardiovascular events. RESULTS: 417 cardiovascular events occurred in 341 patients. Taking into account only the first event by patient (coronary heart disease n = 177, heart failure n = 101, ischaemic stroke n = 63), the incidence rates of cardiovascular events per 100 person years at risk were 15.1 (95% confidence interval 11.8 to 18.4) in those prescribed glucocorticoids and with a diagnosis of iatrogenic Cushing's syndrome, 6.4 (5.5 to 7.3) in those prescribed glucocorticoids without a diagnosis of iatrogenic Cushing's syndrome, and 4.1 (3.4 to 4.8) in those not prescribed glucocorticoids. In multivariate analyses adjusted for sex, age, intensity of glucocorticoid use, underlying disease, smoking status, and use of aspirin, diabetes drugs, antihypertensive drugs, lipid lowering drugs, or oral anticoagulant drugs, the relation between iatrogenic Cushing's syndrome and cardiovascular events was strong (adjusted hazard ratios 2.27 (95% confidence interval 1.48 to 3.47) for coronary heart disease, 3.77 (2.41 to 5.90) for heart failure, and 2.23 (0.96 to 5.17) for ischaemic cerebrovascular events). The adjusted hazard ratio for any cardiovascular event was 4.16 (2.98 to 5.82) when the group prescribed glucocorticoids and with iatrogenic Cushing's syndrome was compared with the group not prescribed glucocorticoids. CONCLUSION: People who use glucocorticoids and exhibit iatrogenic Cushing's syndrome should be aggressively targeted for early screening and management of cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753
Cardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612
Lewis, J. D., Schinnar, R., Bilker, W. B., Wang, X., & Strom, B. L. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1335 · Cited by 602
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
The Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years
Fardet, L., Petersen, I., & Nazareth, I. (2011) · Rheumatology · doi:10.1093/rheumatology/ker017 · Cited by 319
The VAMP research multi-purpose database in the U.K.
Lis, Y. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00137-f · Cited by 116
Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN)
Ruigómez, A., Martín‐Merino, E., & Rodríguez, L. A. G. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1919 · Cited by 89
Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome
Fardet, L., Cabane, J., Kettaneh, A., Lebbe, C., & Flahault, A. (2007) · Rheumatology · doi:10.1093/rheumatology/kem062 · Cited by 59
Self-citation
Cited by
Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017) · BMJ · doi:10.1136/bmj.j2099 · Cited by 1,703
Glucocorticoid receptor signaling in health and disease
Kadmiel, M., & Cidlowski, J. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.07.003 · Cited by 849
Strehl, C., Bijlsma, J. W. J., de Wit, M., Boers, M., Caeyers, N., Cutolo, M., Dasgupta, B., Dixon, W. G., Geenen, R., Huizinga, T. W. J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208916 · Cited by 340
11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess
Morgan, S. A., McCabe, E. L., Gathercole, L. L., Hassan-Smith, Z. K., Larner, D. P., Bujalska, I. J., Stewart, P. M., Tomlinson, J. W., & Lavery, G. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323681111 · Cited by 272
Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas
Debono, M., Bradburn, M., Bull, M., Harrison, B., Ross, R. J., & Newell-Price, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3007 · Cited by 269
Metadata
- Authors
- Fardet, L., Petersen, I., & Nazareth, I.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2012-07-30
- Volume
- 345
- Issue
- jul30 1
- Pages
- e4928-e4928
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2026519059
- Cited by
- 116
- References
- 10
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. https://app.cochat.ai/papers/10.1136/bmj.e4928
- The paper
- Fardet, L., Petersen, I., & Nazareth, I. (2012). Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ. https://doi.org/10.1136/bmj.e4928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.